Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis

Cipla has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib.

This launch marks a decade of Cipla’s foray into IPF treatment medicines, a rare lung disease that impacts ten in one lakh people.

Cipla’s Nintib is priced at Rs 69 (100 mg) and Rs. 85  (150 mg) per capsule.

Cipla introduced Pirfenex, generic Pirfenidone in 2010, the first-ever approved drug for IPF in India. Cipla reduced the cost of its IPF therapy by 40 per cent in 2013 to provide patient-access to this critical treatment.